ERBB2 and breast cancer: In the phase-II NeoSphere trial, 417 patients with HER2-positive breast cancer (≥2 cm) were randomized to 4 treatment arms each compromising 4 cycles: (A) docetaxel plus trastuzumab, (B) docetaxel plus trastuzumab plus pertuzumab, (C) trastuzumab plus pertuzumab without chemotherapy, and (D) docetaxel plus pertuzumab.